1Hacker NF, Barlow EL, Scurry J, et al. Primary surgical manage- ment with tailored adjuvant radiation for stage IB2 cervical cancer [ J]. Obstet Gynecol,2013,121 (4) :765-772. 被引量：1
3Lee TS, Kang SB, Kim YT, et al. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study [ J ]. Radiat Oncol Biol Phys,2013,86(2) :304-310. 被引量：1
4Okazawa M, Mabuchi S, Isohashi F, et M. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience[J]. Int J Gynecol Canc- er, 2013, 23(3) :567-575. 被引量：1
6Srivastava K, Paul S, Chufal KS, et al. Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized phase Ⅲ trial[ J]. Asia Pac J Clin 0ncol,2013,9(4) :349-356. 被引量：1
7Tseng C J, Chang CT, Lai CH, et al. A randomized trial of concur-rent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix[ J]. Gynecol Oncol, 1997,66 (1) :52-58. 被引量：1
8Nam EJ, Lee M, Yim GW,et al. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks [ J ]. Oncologist, 2013,18 (7) : 843 -849. 被引量：1
9Pu J, Qin SS, Ding JX, et al. A randomized controlled study of sin- gle-agent eisplatin and radiotherapy versus doeetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery [ J ]. J Cancer Res Clin Onto/, 2013,139 (4) : 703 -708. 被引量：1
